Molecular Subtype Approximated by Quantitative Estrogen Receptor, Progesterone Receptor and Her2 Can Predict the Prognosis of Breast Cancer

Therapeutic Strategies for Triple-Negative Breast Cancer

(2008) Antoinette R. Tan et al.   CANCER JOURNAL

What is triple-negative breast cancer?

(2008) William J. Irvin et al.   EUROPEAN JOURNAL OF CANCER

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment

(2008) Ke-da Yu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

“Westernizing” Women's Risks? Breast Cancer in Lower-Income Countries

(2008) Peggy Porter   NEW ENGLAND JOURNAL OF MEDICINE